Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease - A Phase II trial of the Southwest Oncology Group

William A.T. Knight, Carol Fabian, John J. Costanzi, Stephen E. Jones, Charles A. Coltman

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 patients with Hodgkin's disease and 11 of 46 patients with lymphoma. Toxicity was acceptable. Methyl-GAG has significant antitumor activity among this group of heavily pretreated patients. Additional trials of methyl-GAG in combination with other agents are underway.

Original languageEnglish (US)
Pages (from-to)235-237
Number of pages3
JournalInvestigational New Drugs
Volume1
Issue number3
DOIs
StatePublished - Sep 1983
Externally publishedYes

Keywords

  • methyl-GAG
  • methyl-GAG in lymphoma
  • MGBG

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease - A Phase II trial of the Southwest Oncology Group'. Together they form a unique fingerprint.

Cite this